It is well established that overuse of short-acting beta-agonists (SABA) increases the risk of poor asthma control, exacerbations, and increased mortality. Several studies have combined a beta-agonist with an inhaled corticosteroid (ICS). The combination provides symptom relief and decreases the risk of poor outcomes. The days of using albuterol monotherapy should be coming to an end; two drugs are better than one!
Guest Authors: Katherine Montag Schafer, PharmD, BCACP, CDCES and Stefanie C. Nigro, PharmD, BCACP, CDCES
Music by Good Talk
Create your
podcast in
minutes
It is Free